Arrowhead Research Corp. (ARWR) Shares Up 3.1%
Shares of Arrowhead Research Corp. (NASDAQ:ARWR) shot up 3.1% during mid-day trading on Friday . The company traded as high as $5.76 and last traded at $5.71, with a volume of 160,275 shares. The stock had previously closed at $5.54.
A number of brokerages recently issued reports on ARWR. Vetr cut Arrowhead Research Corp. from a “buy” rating to a “hold” rating and set a $6.49 price objective on the stock. in a report on Tuesday, April 19th. Jefferies Group reissued a “hold” rating and set a $4.75 price objective on shares of Arrowhead Research Corp. in a report on Wednesday, May 11th. Finally, Chardan Capital started coverage on Arrowhead Research Corp. in a report on Thursday, May 19th. They set a “buy” rating and a $12.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Arrowhead Research Corp. presently has a consensus rating of “Buy” and a consensus target price of $10.27.
The firm has a 50-day moving average price of $5.76 and a 200 day moving average price of $5.05. The firm’s market cap is $343.57 million.
Arrowhead Research Corp. (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.35) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. Equities research analysts predict that Arrowhead Research Corp. will post ($1.40) earnings per share for the current fiscal year.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.